Michael DiMiceli is an Investor at Blue Owl Capital, whose known portfolio counts 10 companies.
Is Michael DiMiceli a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
Contacts
Affiliated funds' portfolios
Investor at Blue Owl Capital, whose known portfolio counts 10 companies
- Mirador Therapeutics
- Pyxis Oncology
- Vestwell
- BridgeBio
- Obsidian Therapeutics
- RLDatix
- enGene
- Alterome Therapeutics
- Monotype
- XOMA
Investor Profile
Founders in the listed sectors FinTech, Healthcare, Real Estate and SaaS, and focus areas Biotech, Cybersecurity, Data Analytics and Direct Lending fall inside that listing.
Stage-wise, the deals at Blue Owl Capital cluster around Growth, Late-Stage and Series A rounds.
What the affiliated firm has backed is the closest available signal on whether Michael DiMiceli is worth approaching.
Colleagues at Blue Owl Capital
Showing 20 of 42
Neel Doppalapudi
Principal
New York, United States
Sara Clarke
Biotech Venture Capital
New York, United States
Christopher Marino
Principal
New York City, United States
Sandip Agarwala
Managing Director
New York, United States
Fabrice Fiol
Investor
New York, United States
Sacha Gornaya
Managing Director
London, United Kingdom
Shari Withem
Managing Director
New York, United States
Daniel Rosato
Managing Director
New York City, United States
Marc Lipschultz
Chief Executive Officer
United States
Julie Ngai
Principal
New York, United States
David Hall
Principal
New York, United States
Pravin Vazirani
Managing Director
Atherton, United States
Thomas Lovinger
Investor
New York, United States
Alex Jones
Managing Director
New York, United States
Alexey Teplukhin
Managing Director
New York City, United States
Brian Finkelstein
Managing Director
New York, United States
Mark Schachter
Managing Director
Dallas, United States
Brendan Kelly
Managing Director
New York, United States
Cara Griffiths
Managing Director
London, United Kingdom
Alyssa Twomey
Principal, Institutional Capital
New York, United States
Frequently asked questions
Who is Michael DiMiceli?
Michael DiMiceli is a private equity investor and venture debt investor based in New York, United States, listed as Investor at Blue Owl Capital. The known portfolio of that firm counts 10 companies. That portfolio belongs to the firm, not to Michael DiMiceli personally.
What does Michael DiMiceli invest in?
Listed sectors include FinTech, Healthcare, Real Estate and SaaS; listed focus areas include Biotech, Cybersecurity, Data Analytics and Direct Lending. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Michael DiMiceli invest at?
Blue Owl Capital appears in Growth, Late-Stage and Series A rounds across its known deals, and Michael DiMiceli is listed there as Investor. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Michael DiMiceli listed at?
Michael DiMiceli is listed as Investor at Blue Owl Capital. 42 other people in the database share a firm with Michael DiMiceli.
How do I contact Michael DiMiceli?
A LinkedIn page is on file for Michael DiMiceli. It is readable inside RaiseHunt after you create an account. The database holds no email address and no phone number for this profile.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 6 September 2026 · How this data is built · Report a correction or request removal